Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
EBERHARD KARLS UNIVERSITÄT TÜBINGEN manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners, resulting in a distribution where each case is reviewed by a different individual. This indicates that the university's prosecution is decentralized, with each application following its own independent path.
The 5 pending office actions are distributed across 3 distinct art units. This concentration suggests that while the examiners are all different, the technical subject matter is focused within 3 specialized areas of Biotechnology & Pharmaceuticals. Practitioners can expect the 5 distinct examiners to have relevant technical expertise for the specific art units involved in the current workload.
PERSONS, JENNA L is the busiest examiner for the portfolio, currently overseeing 1 pending office action. This is consistent with the fact that 5 distinct examiners are handling the pending matters. Without any examiner overlap, the university's legal team must manage independent prosecution tracks, each requiring a unique approach for the specific examiner assigned.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| SANKS, SCHYLER S | 1 | 72.8% | +16.0% |
| WILSON, JERICA KATLYNN | 1 | 61.4% | +39.1% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | WILSON, JERICA KATLYNN | 7d |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | WILSON, JERICA KATLYNN | 7d |
| 19223597 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING | PERSONS, JENNA L | 8d |
| 17924066 | MODULATION OF MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN SIGNALING | CARTER, SANDRA DILLAHUNT | 70d |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | — |
| Art Unit | Apps |
|---|---|
| 1674 | 2 |
| 1637 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19223597 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | 8d | Pending | May 30, 2025 |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | — | §103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | WILSON, JERICA KATLYNN | 1621 | §102§103 | Final Rejection | 7d | Pending | May 05, 2023 |
| 17924066 | MODULATION OF MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN SIGNALING | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Non-Final OA | 70d | Pending | Nov 08, 2022 |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §102§112 | Final Rejection | 70d | Pending | May 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial